Health
ACC 2021: J&J, Bayer pad case for Xarelto in post-surgery artery disease patients – FiercePharma
Bayer and J&J last year showed their legacy blood thinner Xarelto could help post-surgery patients in tough-to-treat artery disease. Now, the partners have data…
With an approval filing already on the FDAs docket, Bayer and Johnson & Johnson are padding their case for launching legacy blood thinner Xarelto in artery disease patients after surgery.
In long-term data from its pivotal trial in peripheral artery disease, Xarelto plus aspirin cut the risk of a variety of clot-related episodesacute clots in the limbs, a major amputation for vascular reasons, heart attack, stroke or cardiovascular deathby 14% compared with aspirin alone in patients who’d had surgery…
-
General16 hours agoInternal Revenue Service starts cutting 20,000 workers
-
Noosa News16 hours agoMan killed, woman seriously injured in collision in Wongabel, Atherton Tablelands, Queensland
-
Noosa News15 hours agoMoreton Bay oyster farm survives cyclone with help of wave wall innovation
-
General20 hours agoWe’ve all talked about potential economic consequences for Australia of Trump’s policies. Now they’re happening